BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.13
8.69
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
Total Liabilities & Equity
BioCryst Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCryst Pharmaceuticals Inc
NASDAQ:BCRX
|
Total Liabilities & Equity
$472.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
39%
|
CAGR 10-Years
13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$143.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$54.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$90.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$22.2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$37.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
|
BioCryst Pharmaceuticals Inc
Glance View
BioCryst Pharmaceuticals, Inc. is a commercial-stage biotechnology company that discovers novel, oral, and small-molecule medicines. The company is headquartered in Durham, North Carolina and currently employs 358 full-time employees. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The firm has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.
See Also
What is BioCryst Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
472.4m
USD
Based on the financial report for Sep 30, 2024, BioCryst Pharmaceuticals Inc's Total Liabilities & Equity amounts to 472.4m USD.
What is BioCryst Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
13%
Over the last year, the Total Liabilities & Equity growth was -10%. The average annual Total Liabilities & Equity growth rates for BioCryst Pharmaceuticals Inc have been 21% over the past three years , 39% over the past five years , and 13% over the past ten years .
You don't have any saved screeners yet
